Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;12(2-3):50-60.
doi: 10.14740/wjon1345. Epub 2021 May 14.

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo

Adeoluwa Akeem Adeniji  1 , Soniya Dulal  2 , Mike G Martin  3
Affiliations
Review

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo

Adeoluwa Akeem Adeniji et al. World J Oncol. 2021 Jun.

Abstract

Personalized medicine (PM) has revolutionized oncology management in high human development indexed countries. By interrogating both disease and host factors through a variety of tools, oncologists have been able to better target an individual's cancer, leading to improved outcomes. But both the tools used to define these variables, such as next generation sequencing, large immunohistochemical and fluorescence in situ hybridization (FISH) panels, and the weapons employed against each target are extremely expensive. The expenses have to be measured as not only the direct cost to the patient but also the cost to the system to develop and deploy the necessary infrastructure to optimally use them. However, the concepts of predictive, timely prevention and PM have demonstrated improvement in patient's satisfaction and cost effectiveness. In this paper we will summarize the relevant barriers and challenges that limit the implementation of PM in the developing world with an emphasis on the challenges in Nigeria and Nepal.

Keywords: Barriers; Cost-efficacy; Developing world; Individualized patient profiling; Oncology; Patient stratification; Personalized medicine.

PubMed Disclaimer

Conflict of interest statement

None to declare.

References

    1. You W, Henneberg M. Cancer incidence increasing globally: The role of relaxed natural selection. Evol Appl. 2018;11(2):140–152. doi: 10.1111/eva.12523. - DOI - PMC - PubMed
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516. - DOI - PubMed
    1. Akin J, Birdsall N, de Ferranti D. Financing Health Services in Developing Countries. The Policy and Research Division of the World Bank's Population, Health, and Nutrition Department.
    1. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–198. doi: 10.1200/EDBK_156686. - DOI - PMC - PubMed
    1. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–187. doi: 10.1038/nrclinonc.2010.227. - DOI - PubMed

LinkOut - more resources